The controversy over the diabetes drug rosiglitazone (Avandia; GlaxoSmithKline), a peroxisome proliferator-activated receptor-γ agonist, has undermined confidence in developing drugs that target this family of nuclear receptors, but some companies still see promise in the field.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Jones, D. Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov 9, 668–669 (2010). https://doi.org/10.1038/nrd3271
Issue date:
DOI: https://doi.org/10.1038/nrd3271
This article is cited by
-
Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
Scientific Reports (2017)
-
Structural exploration of PPARγ modulators through pharmacophore mapping, fragment-based design, docking, and molecular dynamics simulation analyses
Medicinal Chemistry Research (2017)
-
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Endocrine (2013)
-
Portfolio Decisions in Early Development
Pharmaceutical Medicine (2012)
-
Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity
Journal of Computer-Aided Molecular Design (2011)
